| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/520194 |
| P698 | PubMed publication ID | 10476721 |
| P2093 | author name string | Patterson J | |
| Wenzel RP | |||
| Edwards JE Jr | |||
| Dawson J | |||
| Blumberg HM | |||
| Rinaldi M | |||
| Saiman L | |||
| Pfaller M | |||
| Rangel-Frausto MS | |||
| Jarvis W | |||
| Wiblin T | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | intensive care unit | Q5094647 |
| P304 | page(s) | 253-258 | |
| P577 | publication date | 1999-08-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units | |
| P478 | volume | 29 |
| Q27310789 | A mouse model for Candida glabrata hematogenous disseminated infection starting from the gut: evaluation of strains with different adhesion properties |
| Q33709290 | A pre-therapeutic coating for medical devices that prevents the attachment of Candida albicans. |
| Q43670521 | A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion |
| Q36259905 | Advances and challenges in management of invasive mycoses |
| Q37372500 | Advances in Candida detection platforms for clinical and point-of-care applications |
| Q33735943 | An Observational Study on Early Empiric versus Culture-Directed Antifungal Therapy in Critically Ill with Intra-Abdominal Sepsis |
| Q34162712 | An overview of fungal infections |
| Q24244555 | Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients |
| Q24246969 | Antifungal agents for preventing fungal infections in non-neutropenic critically-ill patients |
| Q36967212 | Antifungal agents in neonates: issues and recommendations. |
| Q35775400 | Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data |
| Q35163163 | Antifungal drug therapy in avian species |
| Q34486480 | Antifungal susceptibility testing. New technology and clinical applications |
| Q28366760 | Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999 |
| Q34294880 | Approaches to fungal diagnosis in transplantation |
| Q36633724 | Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis |
| Q30790216 | Association of candidemia and retinopathy of prematurity in very low birthweight infants |
| Q36641985 | Bench-to-bedside review: Candida infections in the intensive care unit |
| Q36527570 | Biology of the pathogenic yeast Candida glabrata |
| Q42035138 | CHROMagar Candida as the sole primary medium for isolation of yeasts and as a source medium for the rapid-assimilation-of-trehalose test |
| Q92592097 | Candida Bloodstream Infection: Changing Pattern of Occurrence and Antifungal Susceptibility over 10 Years in a Tertiary Care Saudi Hospital |
| Q36943829 | Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies |
| Q34753481 | Candida tropicalis in a neonatal intensive care unit: epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen |
| Q43704648 | Candidaemia in cancer patients and in children in a neonatal intensive care unit |
| Q47619707 | Candidemia in critically ill patients: difference of outcome between medical and surgical patients |
| Q35028914 | Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients |
| Q43629922 | Candidiasis among non-neutropenic patients: from colonization to infection |
| Q30434895 | Cell wall mannan and cell surface hydrophobicity in Candida albicans serotype A and B strains |
| Q24195090 | Central venous catheter (CVC) removal for adult patients with candidaemia |
| Q26471135 | Central venous catheter (CVC) removal for patients of all ages with candidaemia |
| Q104384253 | Chemical constituents from Swartzia apetala Raddi var. glabra and evaluation of their antifungal activity against Candida spp. |
| Q37624706 | Clinical aspects of invasive candidiasis in paediatric patients |
| Q37624699 | Clinical aspects of invasive candidiasis in the surgical patient |
| Q30433993 | Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants |
| Q35588482 | Colonization and epithelial adhesion in the pathogenesis of neonatal candidiasis |
| Q35067073 | Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of Candida spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents |
| Q33983259 | Critical annotations to the use of azole antifungals for plant protection |
| Q39051666 | Detection of Candida dubliniensis in Venezuela |
| Q40133371 | Detection of Simulated Candidemia by the BACTEC 9240 System with Plus Aerobic/F and Anaerobic/F Blood Culture Bottles |
| Q41364314 | Detection of bacterial and yeast species with the Bactec 9120 automated system with routine use of aerobic, anaerobic, and fungal media |
| Q40470448 | Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection. |
| Q39758166 | Direct isolation of Candida spp. from blood cultures on the chromogenic medium CHROMagar Candida |
| Q34465297 | EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial |
| Q40771165 | Effect of inoculum size on detection of Candida growth by the BACTEC 9240 automated blood culture system using aerobic and anaerobic media |
| Q77781085 | Electrophoretic karyotyping of Candida albicans strains isolated from premature infants and hospital personnel in a neonatal intensive care unit |
| Q33856434 | Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit |
| Q34373864 | Emerging fungal infections among children: A review on its clinical manifestations, diagnosis, and prevention |
| Q26852351 | Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients |
| Q24303620 | Endogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis |
| Q34273626 | Epidemiology of Candida species infections in critically ill non-immunosuppressed patients |
| Q37327113 | Epidemiology of candidemia in intensive care units |
| Q33183542 | Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. |
| Q34294864 | Epidemiology of fungal infections in solid organ transplant patients |
| Q43200250 | Epidemiology of nosocomial candidaemia in a university hospital: a 12-year study. |
| Q34148751 | Escherichia coli and TNF-alpha modulate macrophage phagocytosis of Candida glabrata |
| Q36734976 | Evaluation of Polymorphic Locus Sequence Typing for Candida glabrata Epidemiology |
| Q90582364 | Evaluation of aminoglycosides utilization in intensive care units of a teaching hospital in southern Iran |
| Q43219915 | Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. |
| Q46815330 | Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure |
| Q36362353 | Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans |
| Q80544534 | Has the epidemiology of nosocomial candidemia changed? |
| Q35917505 | High-dose ascorbate with low-dose amphotericin B attenuates severity of disease in a model of the reappearance of candidemia during sepsis in the mouse |
| Q39628031 | Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit |
| Q36128249 | Impact of selective decontamination of the digestive tract on fungal carriage and infection: systematic review of randomized controlled trials |
| Q40332012 | Impairment of host defense against disseminated candidiasis in mice overexpressing GATA-3 |
| Q43238919 | In vitro investigation of antifungal activity of allicin alone and in combination with azoles against Candida species |
| Q39187666 | In vitro synergistic activity of diketopiperazines alone and in combination with amphotericin B or clotrimazole against Candida albicans |
| Q34194192 | Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland |
| Q46784358 | International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. |
| Q41654518 | Invasive Candida infections in patients of a medical intensive care unit: attempt of improving diagnosis by quantifying the colonization |
| Q36822025 | Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome |
| Q37514625 | Invasive candidiasis: an overview from Taiwan |
| Q45077770 | Is Candida colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals? |
| Q35129035 | Laboratory diagnosis of invasive mycoses |
| Q73235344 | Management of Infections Caused by Candida glabrata |
| Q43082447 | Management of invasive candidiasis in the intensive care unit |
| Q30528889 | NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. |
| Q45191154 | Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates |
| Q35587111 | New approaches to the risk of Candida in the intensive care unit |
| Q35561959 | New signaling pathways govern the host response to C. albicans infection in various niches |
| Q35157647 | Nosocomial infections in adult intensive-care units |
| Q33910250 | One year prospective survey of Candida bloodstream infections in Scotland. |
| Q35550636 | Outcomes of neonatal candidiasis: the impact of delayed initiation of antifungal therapy |
| Q24563657 | Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia |
| Q47980212 | Practices in non-neutropenic ICU patients with Candida-positive airway specimens |
| Q25257510 | Presumptive identification of Candida species other than C. albicans, C. krusei, and C. tropicalis with the chromogenic medium CHROMagar Candida |
| Q34602603 | Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants |
| Q35889819 | Prophylaxis and treatment of invasive candidiasis in the intensive care setting |
| Q36261766 | Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis |
| Q36114466 | Pseudomonas aeruginosa, Candida albicans, and device-related nosocomial infections: implications, trends, and potential approaches for control |
| Q55424061 | Regulated Cell Death as a Therapeutic Target for Novel Antifungal Peptides and Biologics. |
| Q36739864 | Regulation of the Candida albicans cell wall damage response by transcription factor Sko1 and PAS kinase Psk1 |
| Q34569070 | Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences |
| Q33932340 | Risk factors for fluconazole-resistant Candida glabrata bloodstream infections |
| Q34202154 | Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility |
| Q30635445 | Secreted aspartic proteinase family of Candida tropicalis |
| Q44171879 | Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis? |
| Q36465424 | Single-drug therapy or selective decontamination of the digestive tract as antifungal prophylaxis in critically ill patients: a systematic review. |
| Q24625384 | Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges |
| Q39671081 | Synthetic analogues of beta-1,2 oligomannosides prevent intestinal colonization by the pathogenic yeast Candida albicans. |
| Q34207790 | The ALS gene family of Candida albicans |
| Q43013559 | The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice |
| Q37289366 | The damage-response framework of microbial pathogenesis and infectious diseases |
| Q34335391 | The epidemiological profile of candidemia at an Indian trauma care center |
| Q44213511 | The role of the laboratory in the diagnosis and prevention of fungal infections |
| Q33706786 | The use of hybrid phage displaying antigen epitope and recombinant protein in the diagnosis of systemic Candida albicans infection in rabbits and cancer patients |
| Q37374720 | Transcriptional responses of candida albicans to epithelial and endothelial cells. |
| Q37443139 | Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. |
| Q30453032 | Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. |
| Q34540015 | Trends in epidemiology of neonatal sepsis in a tertiary center in Korea: a 26-year longitudinal analysis, 1980-2005. |
| Q43597730 | Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a university hospital |
| Q36898200 | Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study |
| Q34764156 | Use of CHROMagar Candida for the presumptive identification of Candida species directly from clinical specimens in resource-limited settings |
| Q78692764 | Use of simulated blood cultures for time to detection comparison between BacT/ALERT and BACTEC 9240 blood culture systems |
| Q34453437 | Virulence in Candida species |
| Q35179545 | Voriconazole |
| Q74370058 | Yeasts isolated from blood and catheter in children from a public hospital of São Paulo, Brazil |
| Q73972314 | [Epidemiology and prognostic factors of systemic candidiasis in intensive care units] |
| Q82653825 | [Importance of invasive candidiasis in critical non-neutropenic patients] |
| Q82653859 | [Prevention of invasive candidiasis in the critically ill non neutropenic patient] |
Search more.